Skip to main content

Prelude Therapeutics Incorporated (PRLD) Stock Forecast

Data as of May 9, 2026

Healthcare · Current price $4.81 (-6.60%)

Consensus Target
$6.25
Upside
+66.3%
Analysts
2
Rating
Buy(2.00)

Price Target Range

Low $3.00Consensus $6.25High $10.00
▲ Current $4.81

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

Consensus
Buy
Strong Buy0
Buy2
Hold0
Sell0
Strong Sell0

6-Month Trend

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

No analyst price targets available.

PRLD vs Sector & Market

MetricPRLDHealthcare AvgLarge Cap Avg
Analyst Rating2.002.242.41
Analyst Count2819
Target Upside+66.3%+1710.9%+16.4%
P/E Ratio-2.783.3027.60

Revenue Estimates

PeriodLowAvgHigh#
2026-06-30$6M$6M$6M1
2026-09-30$50M$50M$50M1
2026-12-31$7M$7M$7M1
2027-12-31$100M$100M$100M1
2028-12-31$200M$200M$200M1
2029-12-31$100M$100M$100M1
2030-12-31$100M$100M$100M1

EPS Estimates

PeriodLowAvgHigh#
2026-06-30$-0.27$-0.27$-0.271
2026-09-30$0.39$0.39$0.391
2026-12-31$-0.27$-0.27$-0.271
2027-12-31$-0.32$-0.32$-0.321
2028-12-31$0.09$0.09$0.091
2029-12-31$-0.03$-0.03$-0.031
2030-12-31$0.37$0.37$0.371

Frequently Asked Questions

What is the analyst consensus for PRLD?

The consensus among 2 analysts covering Prelude Therapeutics Incorporated (PRLD) is Buy with an average price target of $6.25.

What is the highest price target for PRLD?

The highest analyst price target for PRLD is $10.00.

What is the lowest price target for PRLD?

The lowest analyst price target for PRLD is $3.00.

How many analysts cover PRLD?

2 analysts have issued ratings for Prelude Therapeutics Incorporated in the past 12 months.

Is PRLD a buy or sell right now?

Based on 2 analyst ratings, PRLD has a consensus rating of Buy (2.00/5) with a +66.3% upside to the consensus target of $6.25.

What are the earnings estimates for PRLD?

Analysts estimate PRLD will report EPS of $-0.27 for the period ending 2026-06-30, with revenue estimated at $6M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.